News

We are excited to announce that our patent application for low-volume endotoxin test plate, entitled “Double-layer multi-well plate (US11413619B1)” is granted on Aug. 16, 2022. This innovative plate design significantly reduces LAL and endotoxin reagent consumption, while improving readout accuracy. This patent is a great achievement in addition to our previous patent for single-cell isolation technique. 

The research paper from a South Korean research group uses our 1CellDish^TM (formerly known as SACE) to isolate single cells for single-cell RNA sequencing and SARS-CoV-2 omicron infectivity study. In the study, human alveolar cells are incubated with the viral variants and isolated using 1CellDish^TM for single-cell RNA-seq. The results demonstrate that the Omicron (BA.1) variant is 3-5-fold more infectious to human alveolar cells than the other SARS-CoV-2 variants at the early phase of infection.

A research group at the University of Southampton in the UK has published a paper describing the features and the advantages of 1CellDish^TM single-cell isolation technology. In the study, virally infected primary epithelial cells are successfully isolated using 1CellDish^TM (formerly known as SACE) and generated cDNA libraries of sufficient quality for next-generation sequencing. The paper highlights that the 1CellDish^TM technology is particularly advantageous compared with FACS and Drop-seq and potentially useful for investigating the mechanisms of COVID-19 and other respiratory infections.

Innovative Biochips, LLC excited to announce that our location has been relocated to Sugar Land Business Park. Sugar Land is a city just southwest of Houston and is one of the most affluent and fastest-growing cities in Texas. We are neighboring with many hospitals and pharmaceutical companies as well as high profile companies including Imperial Sugar, Minute Maid, and Schlumberger.

Innovative Biochips, LLC has been awarded a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) Phase II. This Phase II grant ($1,500,000) supports to continue the research and development efforts of Innovative Biochips for developing an automated yeast dissection system initiated in Phase I grant ($225,000).

We are excited to announce that one of our patent applications for single-cell isolation technique, entitled “Microfluidic Aliquoting for Single-Cell Isolation” is granted on Sep. 12, 2017. This innovative invention to provide a technique (method and apparatus) for simple, rapid, and versatile single-cell isolation.

We are delighted to announce that everyone is welcome to our exhibition at American Association for Cancer Research (AACR) Annual Meeting 2017 hold at Washington, DC on April 1 – 5, 2017. Visit out booth and check our innovative product line for single cell isolation and assay.

Innovative Biochips announced today that it has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition, an awards program from the publisher of FierceBiotech and FiercePharma. Innovative Biochips was recognized as a finalist in the category of Biotech Innovation.